Ana Isabel Teruel - Concepedia

Author

Ana Isabel Teruel

Hospital Clínico Universitario de Valencia

Also Known As

A I Teruel, A Oriol, A Teruel, A. I. Teruel, A. Romero Teruel, A. Teruel, A.-I. Teruel, A.I. Teruel, A.‐I. Teruel, Albert Oriol

Publications

1.6K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínico Universitario de Valencia Hospital Universitario de Canarias Hospital Universitario de La Princesa Instituto de Investigación Biomédica de Salamanca Hospital Clínic de Barcelona

About

Ana Isabel Teruel is an author at Hospital Clínico Universitario de Valencia specializing in medicine, hematology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	228
2	Health Sciences	2	2	88
3	Biomedical Engineering	2	2	66
4	Engineering	1	1	13
5	Biostatistics	1	1	13

Ana Isabel Teruel

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Blood	2012	485
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group Sara Alonso, Laura Magnano, Miguel Alcoceba, British Journal of Haematology	2017	76
Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial Laura Rosiñol, Albert Oriol, Ana Isabel Teruel, Leukemia Hematological MalignancyTransplantationMarrow TransplantationOncologyPethema/gem Trial	2017	67
Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study Paula Arana, Bruno Paiva, Noemí Puig, Blood	2015	65
Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd María‐Victoria Mateos, Joaquín Martínez‐López, Paula Rodríguez‐Otero, Blood	2019	62
Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers Rosa Goterris, Juan Carlos Hernández‐Boluda, Ana Isabel Teruel, Bone Marrow Transplantation Regenerative MedicineCell TherapyDifferent StrategiesTransplantationMarrow Transplantation	2005	53
A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib Laura Rosiñol, María Teresa Cibeira, María‐Victoria Mateos, Blood	2010	33
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population Laura Magnano, Sara Alonso, Miguel Alcoceba, British Journal of Haematology	2019	31
Maintenance Therapy After Stem-Cell Transplantation for Multiple Myeloma with Bortezomib/Thalidomide Vs. Thalidomide Vs. alfa2b-Interferon: Final Results of a Phase III Pethema/GEM Randomized Trial Laura Rosiñnol, Albert Oriol, Ana Isabel Teruel, Blood	2012	28
Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome María José Terol, Mar Tormo, José A. Martínez-Climent, Annals of Oncology Lymphoid NeoplasiaMedicineCell AdhesionImmunologyPathology	2003	27

Page 1